209 related articles for article (PubMed ID: 9199659)
1. Effects of Dex-Verapamil on Doxorubicin cytotoxicity in P388 murine leukemia cells.
Noviello E; Allievi E; Russo P; Parodi S
Anticancer Drug Des; 1997 Jun; 12(4):261-76. PubMed ID: 9199659
[TBL] [Abstract][Full Text] [Related]
2. [The effect of finoptin on doxorubicin accumulation in leukemia P-388 cells with induced resistance to the combination of finoptin and doxorubicin].
Moroz LV; Donenko FV; Borovkova NB; Sitdikova SM; Kabieva AO
Biull Eksp Biol Med; 1990 Mar; 109(3):290-2. PubMed ID: 2364157
[TBL] [Abstract][Full Text] [Related]
3. Modulation of doxorubicin efficacy in P388 leukemia following co-administration of verapamil in mini-osmotic pumps.
Slate DL; Fraser-Smith EB; Rosete JD; Freitas VR; Kim YN; Casey SM
In Vivo; 1993; 7(6A):519-23. PubMed ID: 8193270
[TBL] [Abstract][Full Text] [Related]
4. Verapamil effect on the accumulation of doxorubicin in the leukemia P388 cells with induced antibiotic resistance.
Moroz LV; Donenko FV; Borovkova NB; Sitdikova SM
Arch Geschwulstforsch; 1990; 60(2):129-32. PubMed ID: 2339961
[TBL] [Abstract][Full Text] [Related]
5. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.
Fichtner I; Stein U; Hoffmann J; Winterfeld G; Pfeil D; Hentschel M
Anticancer Res; 1994; 14(5A):1995-2003. PubMed ID: 7847840
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine and phenylalanine restriction sensitizes adriamycin-resistant P388 leukemia cells to adriamycin.
Elstad CA; Thrall BD; Raha G; Meadows GG
Nutr Cancer; 1996; 25(1):47-60. PubMed ID: 8837861
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
Tsuruo T; Oh-Hara T; Sudo Y; Naito M
Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
[TBL] [Abstract][Full Text] [Related]
8. [The effect of finoptin on the accumulation of doxorubicin in leukemia P388 cells with induced resistance to the antibiotic].
Moroz LV; Donenko FV; Borovkova NB; Sitdikova SM
Biull Eksp Biol Med; 1989 Dec; 108(12):714-6. PubMed ID: 2634447
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of antitumor activity of pirarubicin by chlorpromazine in mice bearing doxorubicin-resistant P388 leukemia.
Shibata H; Maekawa I; Furusawa S; Kawauchi H; Takayanagi Y; Sasaki K
Res Commun Chem Pathol Pharmacol; 1990 Dec; 70(3):359-62. PubMed ID: 2093213
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity to anthracyclines in P388/dx leukaemia cells.
Bossa R; Dasdia T; Galatulas I; Zunino F
Anticancer Res; 1986; 6(5):1037-9. PubMed ID: 3099628
[TBL] [Abstract][Full Text] [Related]
11. [The cross resistance to cytostatics of leukemia P388 cells with induced resistance to doxorubicin].
Donenko FV; Sitdikova SM; Kabieva AO
Biull Eksp Biol Med; 1993 Sep; 116(9):309-11. PubMed ID: 8118011
[TBL] [Abstract][Full Text] [Related]
12. Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative.
De Jong G; Gelmon K; Bally M; Goldie J; Mayer L
Anticancer Res; 1995; 15(3):911-6. PubMed ID: 7645981
[TBL] [Abstract][Full Text] [Related]
13. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
[TBL] [Abstract][Full Text] [Related]
14. Biological effects of PEMF (pulsing electromagnetic field): an attempt to modify cell resistance to anticancer agents.
Pasquinelli P; Petrini M; Mattii L; Galimberti S; Saviozzi M; Malvaldi G
J Environ Pathol Toxicol Oncol; 1993; 12(4):193-7. PubMed ID: 8189374
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 and mdr-1 gene expression during doxorubicin-induced apoptosis in murine leukemic P388 and P388/R84 cells.
Ramachandran C; You W; Krishan A
Anticancer Res; 1997; 17(5A):3369-76. PubMed ID: 9413174
[TBL] [Abstract][Full Text] [Related]
16. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
17. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
[TBL] [Abstract][Full Text] [Related]
18. Dexamethasone does not enhance antileukemic activity of cladribine in mice with leukemias L1210 and P388.
Robak T; Szmigielska A
Neoplasma; 2000; 47(3):168-71. PubMed ID: 11043840
[TBL] [Abstract][Full Text] [Related]
19. Effect of cepharanthine on doxorubicin cytotoxicity in P388 murine leukemia cells in vitro and in vivo.
Fujimura T; Furusawa S; Kawauchi H; Takayanagi Y; Sasaki K
Res Commun Chem Pathol Pharmacol; 1991 Feb; 71(2):235-8. PubMed ID: 2047569
[TBL] [Abstract][Full Text] [Related]
20. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with a special emphasis on quinacrine.
Inaba M; Maruyama E
Cancer Res; 1988 Apr; 48(8):2064-7. PubMed ID: 3349478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
